Welcome to our dedicated page for COSCIENS Biopharma SEC filings (Ticker: CSCIF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COSCIENS Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COSCIENS Biopharma's regulatory disclosures and financial reporting.
COSCIENS Biopharma Inc. filed a report to share a press release responding to unusual trading in its shares. The company states it is not aware of any material undisclosed information that would explain the recent increase in trading volume and price of its common stock.
The filing also repeats extensive forward-looking statement cautions, highlighting risks tied to potential insolvency proceedings of its German subsidiaries, development and commercialization of its patented natural active ingredients, liquidity and capital resources, and internal controls. COSCIENS describes itself as a life science company focused on plant-based ingredients used in skincare products.
COSCIENS Biopharma Inc., a Canada-based company listed on the TSX and OTCQB, files its annual Form 20-F for the year ended December 31, 2025. The company had 3,183,330 Common Shares outstanding as of December 31, 2025.
COSCIENS focuses on oat-based cosmeceutical and nutraceutical ingredients (including oat beta-glucan and avenanthramides) and on commercializing its licensed PGX Technology for processing biopolymers into high-value materials. A large majority of current revenue comes from a single distribution partner, Symrise AG, under an exclusive supply and distribution agreement that runs to December 31, 2026.
The filing highlights substantial risk, including a disclosed substantial doubt about the company’s ability to continue as a going concern, heavy reliance on Symrise AG for over 84% of revenues, significant financing needs, and exposure to tariffs, raw-material supply disruptions and intense competition. COSCIENS is also managing insolvency proceedings for its German subsidiaries, which may lead to surrendering rights to Macrilen and potential non-cash accounting impacts. Additional risks include possible PFIC tax status for U.S. holders, volatility in its share price, potential TSX delisting, cybersecurity threats, environmental obligations, and prior material weaknesses in internal controls that the company reports as remediated in 2025.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.